Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
281 SEK | +0.07% | +7.66% | +5.24% |
Sales 2024 * | 24.71B 2.26B 188B | Sales 2025 * | 27.13B 2.48B 207B | Capitalization | 95.5B 8.73B 728B |
---|---|---|---|---|---|
Net income 2024 * | 3.38B 309M 25.76B | Net income 2025 * | 4.89B 447M 37.27B | EV / Sales 2024 * | 4.5 x |
Net Debt 2024 * | 15.74B 1.44B 120B | Net Debt 2025 * | 10.71B 979M 81.65B | EV / Sales 2025 * | 3.91 x |
P/E ratio 2024 * |
28.4
x | P/E ratio 2025 * |
19.9
x | Employees | 1,752 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.87% |
Latest transcript on Swedish Orphan Biovitrum AB
1 day | +0.07% | ||
1 week | +7.66% | ||
Current month | +5.16% | ||
1 month | +4.93% | ||
3 months | -2.02% | ||
6 months | +28.66% | ||
Current year | +5.24% |
Managers | Title | Age | Since |
---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 59 | 22/17/22 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 57 | 20/18/20 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Sven Ullman
BRD | Director/Board Member | 68 | 01/21/01 |
Annette Clancy
CHM | Chairman | 70 | 08/14/08 |
Staffan Schüberg
BRD | Director/Board Member | 55 | 01/20/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.15% | 233 M€ | +8.82% | ||
0.90% | 5 M€ | +8.63% | ||
0.69% | 148 M€ | +7.01% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 281 | +0.07% | 1,124,638 |
25/24/25 | 280.8 | +5.41% | 1,324,807 |
24/24/24 | 266.4 | -0.97% | 886,847 |
23/24/23 | 269 | +2.36% | 667,027 |
22/24/22 | 262.8 | +0.69% | 414,483 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:59 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.24% | 8.71B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- SOBI Stock